Neok Bio launched with a $75 million Series A, backed principally by ABL Bio, to advance two bispecific antibody‑drug conjugates (ADCs) toward IND filings. The Palo Alto startup claims its bispecific ADCs can overcome limitations of conventional ADCs by targeting unique target pairs to increase tumor selectivity and payload delivery. The company expects to file INDs for both programs in the coming months and emphasized preclinical efficacy and a differentiated conjugation platform inherited from ABL’s discovery work. Neok’s approach reflects renewed investor interest in next‑generation ADC modalities that seek wider therapeutic windows in solid tumors. Investors will watch early safety and manufacturability readouts closely; ADC development remains capital‑intensive and technically demanding, with success dependent on target selection and linker‑payload chemistry.